CSA Medical has secured $20.5 million in a Series B financing to support its currently marketed Spray Cryotherapy system. Intersouth Partners and First Analysis led the financing, with S.V. Life Sciences, Rose Park, Blue Heron Capital and other existing investors participating. The system is comprised of a device and specialty catheters that allow delivery of therapeutic doses of a cryogen to freeze and destroy unwanted tissue inside the body. CSA release